COVID-19 Disease Prevention June 2023: FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the 2023-2024 composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant (ie, XBB.1.5) Mechanism of Action The goal of vaccination is to elicit long-term antigen-specific antibody responses by plasma cells and to develop persistent T-cell and B-cell memory of the antigen (ie, humoral and cellular immune response) Contains purified full-length protein subunit (rS); an immune response to the rS protein is elicited, which protect against COVID-19 Vaccine contains an adjuvant (ie, saponin-based Matrix-MTM) to enhance immune response and stimulate high levels of neutralizing antibodies No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print